Monograph Details
|
|
Gastrointestinal Tract
> Nausea
|
|
MARINOL |
| Manufacturer |
|
Unimed Pharmaceuticals, Inc. |
| Legal Classification |
|
CIII |
| Pharmacological Class |
|
Cannabinoid. |
| Generic Name |
|
Dronabinol 2.5mg, 5mg, 10mg; caps; contains sesame oil. |
| Indications |
|
Refractory nausea and vomiting associated with cancer chemotherapy. |
| Adults and Children |
|
Individualize. Initially 5mg/m2 1–3 hrs before chemotherapy. Then every 2–4 hrs after chemo; max 4–6 doses daily. May increase if needed by increments of 2.5mg/m2; max dose 15mg/m2. |
| Precautions |
|
Seizure or cardiac disorders. History of psychiatric disorders (eg, mania, depression, schizophrenia) or substance abuse. Write Rx for smallest practical amount. Keep patient under responsible adult supervision (esp. when dose is adjusted). Children. Elderly (monitor: esp. with dementia). Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Potentiates CNS depression with benzodiazepines, barbiturates, alcohol, other CNS depressants and other psychoactive substances (avoid). May affect, or be affected by other drugs that are highly protein bound (eg, sympathomimetics, anticholinergics, tricyclic antidepressants). Antagonizes theophylline. Phenothiazines may potentiate effect without additional toxicities. |
| Adverse Reactions |
|
Psychomimetic reactions, euphoria, depression, behavior disorders, drowsiness, dizziness, fatigue, somnolence, altered mental status, seizures (discontinue if occurs), ataxia, anxiety, paresthesia, tachycardia, hypotension, vasodilation, tolerance and withdrawal syndrome. |
| How Supplied |
|
Caps—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
